ALNY (Alnylam Pharmaceuticals, Inc.) — AI Stock Analysis & Recommendation

Research of October 29, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate ALNY a HOLD. The latest price is $174.00.

The research plan

• Entry: $174.00
• Time horizon: days

The current setup does not warrant a BUY recommendation, thus no defined time horizon for a trade.

Why

The current setup does not warrant a BUY recommendation, thus no defined time horizon for a trade. Catalysts to watch: Significant earnings surprise with a +622.7% EPS beat; Strong fundamental indicators like 66.9% YoY revenue growth and a low PEG ratio of 0.3; Positive social media sentiment driven by earnings and clinical data. Key risks: Strong bearish technical trend and low volume indicating lack of institutional conviction; High volatility and significant recent drawdown (-34.9% from 60-day high); Biotech-specific risks including clinical trial outcomes and potential cash runway issues.

What could push ALNY higher

• Significant earnings surprise with a +622.7% EPS beat.
• Strong fundamental indicators like 66.9% YoY revenue growth and a low PEG ratio of 0.3.
• Positive social media sentiment driven by earnings and clinical data.

Key risks for ALNY

• Strong bearish technical trend and low volume indicating lack of institutional conviction.
• High volatility and significant recent drawdown (-34.9% from 60-day high).
• Biotech-specific risks including clinical trial outcomes and potential cash runway issues.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

Alnylam Pharmaceuticals is fundamentally undervalued, driven by exceptional revenue growth, a strong competitive moat with its RNAi platform, and significant upside potential indicated by analyst targets. While leverage is a consideration, robust cash reserves and strong operational performance mitigate this risk, supporting a bullish outlook.

• Analyst mean target of $367.78 implies ~111% upside from current price of $174.0.
• Revenue growth YoY is 66.9%, indicating strong top-line expansion and market traction.
• The company's PEG ratio of 0.3 suggests its forward P/E is well below its expected earnings growth, indicating potential undervaluation relative to growth prospects.

Technical team: Bearish

Despite mixed signals from volume and momentum, the overwhelming bearish trend and chart patterns indicate a strong likelihood of further downside. The current price is trading near a key level, but the established downtrend and bearish formations suggest a breakdown is more probable than a reversal.

• The stock is in a strong downtrend, trading well below all key moving averages and has broken through the last visible support level, suggesting further downside potential.
• The stock is trading sideways with low volume, showing no clear trend or strong institutional activity, making it a neutral signal.
• The indicators are mixed, with a neutral RSI, bearish MACD, and a potential bullish signal from the Stochastic oscillator, suggesting a sideways trend with no clear immediate trading signal.

Sentiment team: Neutral

Alnylam Pharmaceuticals exhibits a mixed sentiment profile, with positive news and social media buzz around earnings and pipeline developments countered by significant analyst downgrades and valuation concerns. While institutional ownership remains high, the recent wave of negative analyst commentary and insider selling suggests a cautious outlook, leading to a neutral overall verdict with stable momentum.

• The news sentiment is neutral, driven by a positive earnings surprise but tempered by valuation concerns, development delays, and a recent analyst downgrade. (Score: 0.062)
• Social media sentiment is positive, fueled by strong Q3 earnings, promising clinical data, and favorable analyst ratings, though concerns about pricing investigations and drug dependence exist. (Score: 0.25)
• Analyst sentiment is neutral, with high institutional ownership and decreasing short interest offset by numerous recent downgrades and price target cuts, alongside mixed insider activity.

Risk team: High

ALNY presents a high-risk profile due to significant historical drawdowns, extreme volatility, and the inherent binary risks associated with biotech pipeline development and regulatory approvals. The company's reliance on successful clinical trials and commercialization, coupled with potential dilution risks, necessitates a cautious approach with a small position size and robust risk management strategies.

• Deep Drawdown and High Volatility: ALNY has experienced a significant 1-year drawdown (-64.58%) and exhibits high realized and implied volatility, indicating substantial price swings and potential for further sharp declines.
• Pipeline and Clinical Trial Risk: As a biotech company, ALNY's success is heavily dependent on the outcomes of its clinical trials and regulatory decisions, which are binary events that can cause dramatic price movements.
• Cash Runway and Dilution Risk: Ongoing R&D and potential for prolonged development cycles suggest a reliance on future funding, increasing the risk of equity dilution.

ALNY at a glance

Market value	$30.5B
Price / earnings	95.3
Revenue growth (year over year)	65.2%
Profit margin	19.7%
Debt / equity	0.50

Every AI call on ALNY since September 7, 2026, and what happened next (2 calls) →

Research of October 29, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.